Bilateral intrahippocampal NAC61-95 effects on behavior and moderation with l-NAME treatment

Neuroscience Research

Volumn 66, Issue 2, 2010, Pages 213-218

  O'Hare, Eugene ^a   Elliott, Jennifer J ^a   Hobson, Peter ^b   O'Mara, Shane M ^c   Spanswick, David ^d   Kim, Eun Mee ^e  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Dementia; Inflammation; l NAME; Nitric oxide synthase; Operant behavior; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; N(G) NITROARGININE METHYL ESTER; WATER; ENZYME INHIBITOR; PEPTIDE FRAGMENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR DISORDER; BEHAVIORAL RESEARCH; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HIPPOCAMPUS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; ANALYSIS OF VARIANCE; ANIMAL; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INSTRUMENTAL CONDITIONING; MALE; SPRAGUE DAWLEY RAT;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; ASTROCYTES; CA3 REGION, HIPPOCAMPAL; CONDITIONING, OPERANT; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; MALE; NG-NITROARGININE METHYL ESTER; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 74249084922     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2009.11.002     Document Type: Article

References (60)

1. Albani D., Peverelli E., Rametta S., Batelli S., Veschini L., Negro A., and Forloni G.L. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB J. 18 (2004) 1713-1715
2. Barthwal M.K., Srivastava N., and Dikshit M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep. 6 (2001) 297-302
3. Bayer T.A., Jakaia P., Hartmann T., Egensperger R., Busiei R., Falkai P., and Beyreuther K. Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport 10 (1999) 2799-2803
4. Bodles A.M., Guthrie D.J.S., Harriott P., Campbell P., and Irvine G.B. Toxicity of non-Aβ component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β-sheet structure and fibrils. Eur. J. Biochem. 167 (2000) 2186-2194
5. Broghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., and Tabaton M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neuro Lett. 287 (2000) 65-67
6. Bursztyn M., Mekler J., Peleg E., and Bernheim J. Subpressor dose of l-NAME unmasks hypertensive effect of chronic hyperinsulinemia. Hypertension 36 (2000) 872-877
7. Buter T.C., van den Hout A., Matthews F.E., Larsen J.P., Brayne C., and Arsland D. Dementia and survival in Parkinson's disease. A 12-year population study. Neurology 70 (2008) 1017-1022
8. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K.H. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
9. Crow J.P., and Beckman J.S. Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Adv. Pharmocol. 34 (1995) 17-43
10. Dexter D.T., Carter C.T., Wells F.R., Javoy-Agid F., Lees A., Jenner P., and Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52 (1989) 381-390
11. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., and Marsden C.D. Alternations in the levels of iron, ferritin, and other trace metals in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia. Brain 144 (1991) 1953-1975
12. Dhmer T., Lindenau J., Haid S., Dichgans J., and Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74 (2000) 2213-2216
13. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., and Tanner C.M. Projected number of people with Parkinson's disease in the most populous nations, 2005 through 2030. Neurology 68 (2005) 384-386
14. Du W., and Harvey J.A. The nitric oxide synthase inhibitor l-NAME facilitates associative learning. Prog. Neuropsychopharm. Biol. Psychiatry 20 (1996) 1183-1195
15. Du H.N., Tang L., Lou X.Y., Li H.T., Hu J., Zhou J.W., and Hu H.Y. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillisation and cytotoxicity of human alpha-synuclein. Biochemistry 42 (2003) 8870-8878
16. El-Agnaf O.M., Bodles A.M., Guthrie D.J.S., Harriott P., and Irvine G.B. The N-terminal region of non Aβ component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur. J. Biochem. 15 (1998) 157-163
17. El-Agnaf O.M., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., Curran M.D., Court J.A., Mann D.M., Ikeda S., Cookson M.R., Hardy J., and Allsop D. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17 (2003) 1945-1947
18. El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., Schlossmacher M.G., and Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20 (2006) 419-425
19. Eve D.J., Nisbet A.P., Kingsbury A.E., Hewson E.L., Daniel S.E., Lees A.J., Marsden C.D., and Foster O.J. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res. 63 (1998) 62-71
20. Ferrante R.J., Hantraye P., Briouillet E., and Beal M.F. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res. 823 (1999) 177-182
21. Forloni G., Bertani I., Calella A.M., Thaler F., and Invernizzi R. Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann. Neurol. 47 (2000) 632-640
22. Gaisson B.I., Duda J.E., Murray I.V.J., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., and Lee V.M. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290 (2000) 985-989
23. Good P.F., Hsu A., Werner P., Perl D.P., and Olanow C.W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57 (1998) 338-342
24. Haroutunian V., Serby M., Purohit D.P., Perl D.P., Marin D., Lantz M., Mohs R.C., and Davis K.L. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer's disease neuropathological conditions. Arch. Neurol. 57 (2000) 1145-1150
25. Hibbs J.B., Vavrin Z., and Taintor R.E. l-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J. Immunol. 138 (1987) 550-565
26. Hobson J.P., and Meara R.J. The risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov. Disord. 19 (2004) 1043-1049
27. Hong D.P., Fink A.L., and Uversky V.M. Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation?. Biochim. Biophys. Acta 1794 (2009) 282-290
28. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.I., Lee V.M., Clark C.M., Glosser G., Stern M.B., Gollomp S.M., and Arnold S.E. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54 (2000) 1916-1921
29. Iravani M.M., Kashefi K., Mander P., Rose S., and Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110 (2002) 49-58
30. Jakes R., Spillantini M.G., and Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 345 (1994) 27-32
31. Kahle P.J., Neumann M., Ozmen L., Muller V., Odoy S., Okamoto N., Jacobsen H., Iwatsubo T., Trojanowski J.Q., Takahashi H., Wakabayashi K., Bogdanovic N., Riederer P., Kretzschmar H.A., and Haass C. Selective insolubility of α-synuclein in human Lewy body disease is recapitulated in a transgenic mouse model. Am. J. Pathol. 159 (2001) 2215-2225
32. Klegeris A., Giasson B.I., Zhang H., Maguire J., Pelech S., and McGeer P.L. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J. 20 (2006) 2000-2008
33. Law A., Dore S., Blackshaw S., Gauthier S., and Quirion R. Alternation of expression levels of neuronal nitric oxide synthase and haem oxygenase-2 messenger RNA in the hippocampi and cortices of young adult and aged cognitively impaired and impaired Long-Evans rats. Neuroscience 100 (2000) 769-775
34. Lee E.N., Cho H.J., Lee C.H., Lee D., Chung K.C., and Paik S. Pathalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein. Biochemistry 43 (2004) 3704-3715
35. Lee H.J., Patel S., and Lee S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25 (2005) 6016-6024
36. Litvan I., Mohr E., Williams J., Gomez C., and Chace T.N. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 54 (1991) 25-29
37. Liu B., Gao H.M., and Hong J.S. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ. Health Perspect. 111 (2003) 1065-1073
38. Maroteaux L., Campanelia J.T., and Scheller R.H. Synuclein: a neuron specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8 (1988) 2804-2815
39. Maroteaux L., and Scheller R.H. The rat brain synucleins: a family of proteins transiently associated neuronal membrane. Mol. Brain Res. 11 (1991) 335-343
40. Marras C., and Lang A. Changing concepts in Parkinson's disease: moving beyond a decade of the brain. Neurology 70 (2008) 1996-2003
41. Mattila P.M., Koskela T., Roytta M., Lehtimaki T., Pirttila T.A., and Ilveskoski E. Apolipoprotein E epsillon4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology. Acta Neuropathol. 96 (1998) 417-420
42. Munch G., Luth H.J., Wong A., Arendt T., Hirsch E., Ravid R., and Riederer P. Crosslinking of alpha-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation?. J. Chem. Neuroanat. 20 (2000) 253-257
43. Muramatsu Y., Kurosaki R., Mikami T., Michimata M., Matsubara M., Imai Y., Kato H., Itoyama Y., and Araki T. Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice. Metab. Brain Dis. 17 (2002) 169-182
44. O'Hare E., Weldon D.T., Mantyh P.W., Ghilardi J.R., Finke M.P., Kuskowski M.A., Maggio J., Shephard R.A., and Cleary J. Delayed behavioral effects following intrahippocampal injection of aggregated Abeta (1-42). Brain Res. 815 (1999) 1-10
45. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, San Diego
46. Pitsikas N. The nitric oxide (NO) donor molsidomine antagonizes scopolamine and l-NAME-induced performance deficits in a spatial memory task in the rat. Behav. Brain Res. 200 (2009) 160-164
47. Poling A., Morgan-Paisley K., Panos K.J., Kim E.-M., O'Hare E., Cleary J.P., Lesne S., Ashe K.H., Porritt M., and Baker L.E. Oligomers of the amyloid-β protein disrupt working memory: confirmation with two behavioural procedures. Behav. Brain Res. 193 (2008) 230-234
48. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., and Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 4565-4571
49. Richardson R.L., Kim E.-M., Shephard R.A., Gardiner T., Cleary J., and O'Hare E. Behavioral and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res. 954 (2002) 1-10
50. Seo J.H., Rah J.C., Choi S.H., Shin J.K., Min K., Kim H.S., Park C.H., Kim S., Kim E.M., Lee S.H., Suh S.W., and Suh Y.H. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and P13/Akt kinase pathway. FASEB J. 16 (2002) 1826-1828
51. Singh S., Das T., Ravindran A., Chaturvedi R.K., Shukla Y., Agarwl A.K., and Dikshit M. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease. Redox Rep. 10 (2005) 103-109
52. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6469-6473
53. Sung J.Y., Kim J., Paik S.R., Park J.H., Ahn Y.S., and Chung K.C. Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J. Biol. Chem. 276 (2001) 27441-27448
54. Townsend M., Cleary J.P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D.M., and Selkoe D.J. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol. 60 (2006) 668-676
55. Treves A., and Rolls E.T. Computational analysis of the role of the hippocampus in memory. Hippocampus 4 (2004) 374-391
56. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yshimoto M., Otero D.A., Kondo J., Ihara Y., and Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11282-11286
57. Weldon D.T., O'Hare E., Kuskowski M.A., Cleary J., and Mach Jr. J.R. Alternating-lever cyclic-ratio schedule analysis of the effects of atropine sulphate. Pharmacol. Biochem. Behav. 54 (1996) 753-757
58. Weldon D.T., Rogers S.D., Ghilardi J.R., Finke M.P., Cleary J.P., O'Hare E., Estler W.P., Maggio J.E., and Mantyh P.W. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci. 18 (1998) 2161-2173
59. Zhang Z.X., and Roman G.C. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 12 (1993) 195-208
60. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J.S., and Zhang J. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19 (2005) 533-542